Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV000711303 | SCV000841643 | uncertain significance | not provided | 2018-06-05 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001049653 | SCV001213718 | benign | Cohen syndrome | 2024-01-29 | criteria provided, single submitter | clinical testing | |
Institute of Human Genetics, |
RCV001049653 | SCV001440448 | uncertain significance | Cohen syndrome | 2019-01-01 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV001049653 | SCV001529784 | uncertain significance | Cohen syndrome | 2018-01-29 | criteria provided, single submitter | clinical testing | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. |
Ce |
RCV000711303 | SCV002586238 | uncertain significance | not provided | 2022-08-01 | criteria provided, single submitter | clinical testing | VPS13B: PM2:Supporting, BP4 |
Ambry Genetics | RCV002397496 | SCV002672148 | uncertain significance | Inborn genetic diseases | 2018-02-14 | criteria provided, single submitter | clinical testing | The p.D2582N variant (also known as c.7744G>A), located in coding exon 41 of the VPS13B gene, results from a G to A substitution at nucleotide position 7744. The aspartic acid at codon 2582 is replaced by asparagine, an amino acid with highly similar properties. This amino acid position is not conserved however, asparagine is a reference amino acid in several species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Prevention |
RCV003424304 | SCV004116519 | uncertain significance | VPS13B-related disorder | 2024-02-07 | criteria provided, single submitter | clinical testing | The VPS13B c.7669G>A variant is predicted to result in the amino acid substitution p.Asp2557Asn. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.040% of alleles in individuals of European (Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |
Natera, |
RCV001049653 | SCV001460401 | uncertain significance | Cohen syndrome | 2019-11-11 | no assertion criteria provided | clinical testing |